Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Costimulatory wars: the tumor menace.

A A Hurwitz1, E D Kwon, A van Elsas

  • 1Department of Microbiology, State University of New York, Upstate Medical University, Syracuse 13210, USA. hurwitza@mail.upstate.edu

Current Opinion in Immunology
|September 28, 2000
PubMed
Summary

Novel T cell costimulatory molecules offer new avenues for cancer immunotherapy. Recent advances in CTLA-4 blockade, B7-family members, CD40, and OX40 are enhancing immunomodulatory cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isotype selection for antibody-based cancer therapy.

Clinical and experimental immunology·2020
Same author

Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.

Prostate cancer and prostatic diseases·2016
Same author

MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.

Oncogene·2012
Same author

Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform.

Systems biology·2006
Same author

Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2001

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • T cell costimulatory molecules play a crucial role in immune responses.
  • Understanding these molecules is key to developing effective cancer immunotherapies.
  • Previous research has laid the groundwork for targeting costimulatory pathways.

Purpose of the Study:

  • To review recent advances in T cell costimulatory molecules for tumor immunotherapy.
  • To highlight novel approaches in modulating these molecules for enhanced cancer treatment.
  • To discuss the contribution of these advances to the development of powerful immunomodulatory cancer therapies.

Main Methods:

  • Review of recent studies on T cell costimulatory molecules.
  • Analysis of combinatorial immunotherapy strategies.

Related Experiment Videos

  • Focus on specific molecules: CTLA-4, B7-family, CD40, and OX40.

    • Main Results:

    • Significant progress has been made in understanding T cell costimulatory molecules.
    • Novel approaches, including CTLA-4 blockade and B7-family member identification, have emerged.
    • Modulation of CD40 and OX40 shows promise in reversing tolerance and enhancing antitumor responses.

    Conclusions:

    • Advances in T cell costimulatory molecules have expanded the landscape of cancer immunotherapy.
    • Combinatorial approaches leveraging these molecules offer more potent immunomodulatory effects.
    • Targeting costimulatory pathways represents a promising strategy for developing next-generation cancer therapies.